Giuseppe
Emeritus
Vaccine. 2008 Dec 15. [Epub ahead of print]
Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination.
Ohmit SE, Gross J, Victor JC, Monto AS. - University of Michigan School of Public Health, 109 Observatory Street, Ann Arbor, MI 48109, USA.
Data collected as part of a multi-year trial examining the efficacies of inactivated and live-attenuated influenza vaccines were used to evaluate the reported occurrence of post-vaccination reactions.
Two cohorts were defined:
(1) individuals who received the same vaccine over two consecutive years, and
(2) individuals who first enrolled in year 2 of the study and received vaccine only in that year.
For both vaccines there were significantly fewer reactions reported in year 2 in those subjects who were vaccinated both years.
Declines were demonstrated when comparing year 1 and 2 reaction frequencies in subjects vaccinated both years, and differences were seen when comparing year 2 reaction frequencies in subjects vaccinated both years with those first vaccinated in year 2.
Reaction reporting peaked on post-vaccination days 0 and 1 following receipt of the inactivated vaccine, and on day 2 following receipt of the live-attenuated vaccine.
Data collected as part of a multi-year trial examining the efficacies of inactivated (TIV) and live-attenuated influenza (LAIV) were used to evaluate the reported occurrence of post-vaccination reactions.
Two cohorts were defined:
(1) individuals who received the same vaccine over two consecutive years, and
(2) individuals who first enrolled in year 2 of the study and received vaccine only in that year.
For both vaccines there was significantly lower reactions reported in year 2 in those subjects who were vaccinated both years.
Declines were also demonstrated when comparing year 2 reaction frequencies in subjects vaccinated both years with those first vaccinated in year 2. For TIV, reactions peaked on post-vaccination days 0 and 1 and then declined. For LAIV reactions (typically runny nose/congestion) peaked on day 2.
PMID: 19095028 [PubMed - as supplied by publisher]
-
------
Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination.
Ohmit SE, Gross J, Victor JC, Monto AS. - University of Michigan School of Public Health, 109 Observatory Street, Ann Arbor, MI 48109, USA.
Data collected as part of a multi-year trial examining the efficacies of inactivated and live-attenuated influenza vaccines were used to evaluate the reported occurrence of post-vaccination reactions.
Two cohorts were defined:
(1) individuals who received the same vaccine over two consecutive years, and
(2) individuals who first enrolled in year 2 of the study and received vaccine only in that year.
For both vaccines there were significantly fewer reactions reported in year 2 in those subjects who were vaccinated both years.
Declines were demonstrated when comparing year 1 and 2 reaction frequencies in subjects vaccinated both years, and differences were seen when comparing year 2 reaction frequencies in subjects vaccinated both years with those first vaccinated in year 2.
Reaction reporting peaked on post-vaccination days 0 and 1 following receipt of the inactivated vaccine, and on day 2 following receipt of the live-attenuated vaccine.
Data collected as part of a multi-year trial examining the efficacies of inactivated (TIV) and live-attenuated influenza (LAIV) were used to evaluate the reported occurrence of post-vaccination reactions.
Two cohorts were defined:
(1) individuals who received the same vaccine over two consecutive years, and
(2) individuals who first enrolled in year 2 of the study and received vaccine only in that year.
For both vaccines there was significantly lower reactions reported in year 2 in those subjects who were vaccinated both years.
Declines were also demonstrated when comparing year 2 reaction frequencies in subjects vaccinated both years with those first vaccinated in year 2. For TIV, reactions peaked on post-vaccination days 0 and 1 and then declined. For LAIV reactions (typically runny nose/congestion) peaked on day 2.
PMID: 19095028 [PubMed - as supplied by publisher]
-
------